Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG
绝经后激素敏感性乳腺癌患者芳香化酶抑制剂相关骨丢失（AIBL）的管理：国际骨质疏松症基金会（IOF）、加拿大骨质疏松症协会（CABS）、欧洲骨质疏松症和骨质疏松症学会（ECTS）、国际骨质疏松症和骨质疏松症学会（IEG）、欧洲骨质疏松症和骨质疏松症学会（ESCEO IMS）以及国际骨质疏松症和骨质疏松症学会（SIOG）的联合立场声明
期刊:Journal of Bone Oncology
影响因子:3.5
doi:10.1016/j.jbo.2017.03.001
Hadji, Peyman; Aapro, Matti S; Body, Jean-Jacques; Gnant, Michael; Brandi, Maria Luisa; Reginster, Jean Yves; Zillikens, M Carola; Glüer, Claus-C; de Villiers, Tobie; Baber, Rod; Roodman, G David; Cooper, Cyrus; Langdahl, Bente; Palacios, Santiago; Kanis, John; Al-Daghri, Nasser; Nogues, Xavier; Eriksen, Erik Fink; Kurth, Andreas; Rizzoli, Rene; Coleman, Robert E
肿瘤
肿瘤免疫
多发性硬化症
乳腺癌
代谢
骨质疏松
免疫/内分泌
